BR112012016128A8 - Agente terapêutico (y-39983) para disfunção endotelial da córnea - Google Patents

Agente terapêutico (y-39983) para disfunção endotelial da córnea

Info

Publication number
BR112012016128A8
BR112012016128A8 BR112012016128A BR112012016128A BR112012016128A8 BR 112012016128 A8 BR112012016128 A8 BR 112012016128A8 BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A8 BR112012016128 A8 BR 112012016128A8
Authority
BR
Brazil
Prior art keywords
corneal endothelial
endothelial cells
compound
therapeutic agent
corneal
Prior art date
Application number
BR112012016128A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012016128A2 (pt
Inventor
Takahashi Hiroaki
Sakamoto Yuji
Kida Tetsuo
Tarui Takeshi
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Publication of BR112012016128A2 publication Critical patent/BR112012016128A2/pt
Publication of BR112012016128A8 publication Critical patent/BR112012016128A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012016128A 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea BR112012016128A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (2)

Publication Number Publication Date
BR112012016128A2 BR112012016128A2 (pt) 2016-05-31
BR112012016128A8 true BR112012016128A8 (pt) 2017-12-05

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016128A BR112012016128A8 (pt) 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea

Country Status (10)

Country Link
US (1) US20120288482A1 (OSRAM)
EP (1) EP2519237A1 (OSRAM)
JP (2) JP5750444B2 (OSRAM)
KR (1) KR20120099147A (OSRAM)
CN (1) CN102770136A (OSRAM)
BR (1) BR112012016128A8 (OSRAM)
CA (1) CA2785851A1 (OSRAM)
MX (1) MX2012007671A (OSRAM)
RU (1) RU2563141C2 (OSRAM)
WO (2) WO2011080984A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3178138A1 (en) 2011-12-06 2013-06-13 Astellas Institute For Regenerative Medicine Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
JP6470286B2 (ja) 2013-11-27 2019-02-13 京都府公立大学法人 ラミニンの角膜内皮細胞培養への応用
US10959997B2 (en) 2013-12-27 2021-03-30 Kyoto Prefectural Public University Corporation Combined agent for cell therapy of corneal endothelial cell
CN106604730B (zh) * 2014-09-24 2019-12-20 兴和株式会社 角膜厚度调节剂
BR112017008805A2 (pt) 2014-10-31 2017-12-19 Kyoto Prefectural Public Univ Corp tratamento de córnea usando laminina
US11918630B2 (en) 2014-10-31 2024-03-05 Kyoto Prefectural Public University Corporation Treatment of retina and nerve using laminin
JP7008337B2 (ja) * 2016-02-15 2022-02-10 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CA2707827A1 (en) 2001-04-11 2002-10-24 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005118582A1 (ja) * 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
JPWO2006057270A1 (ja) * 2004-11-26 2008-06-05 旭化成ファーマ株式会社 含窒素３環化合物
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
US20090062295A1 (en) * 2005-03-10 2009-03-05 Mitsubishi Pharma Corporation Pharmaceutical Products
EP1980274B1 (en) * 2006-01-19 2016-03-23 Senju Pharmaceutical Co., Ltd. Corneal endothelial preparation which enables cells to grow in vivo
MX2009001037A (es) * 2006-07-31 2009-05-15 Senju Pharma Co Preparacion liquida acuosa que contiene compuesto de amida.
KR20180031066A (ko) 2007-08-29 2018-03-27 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
WO2011080984A1 (en) 2011-07-07
JP2015155460A (ja) 2015-08-27
CN102770136A (zh) 2012-11-07
EP2519237A1 (en) 2012-11-07
US20120288482A1 (en) 2012-11-15
CA2785851A1 (en) 2011-07-07
MX2012007671A (es) 2012-08-23
KR20120099147A (ko) 2012-09-06
JP2013515676A (ja) 2013-05-09
BR112012016128A2 (pt) 2016-05-31
JP5750444B2 (ja) 2015-07-22
RU2012132443A (ru) 2014-02-10
WO2011081221A1 (en) 2011-07-07
RU2563141C2 (ru) 2015-09-20

Similar Documents

Publication Publication Date Title
EP4512484A3 (en) Excipients for nicotine-containing therapeutic compositions
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
BR112012016128A2 (pt) agente terapêutico (y-39983) para disfunção endotelial da córnea
NZ597059A (en) Inhibitors of influenza viruses replication
MX348245B (es) Tratamiento de la degeneracion del disco intervertebral mediante el uso de celulas humanas derivadas de tejido del cordon umbilical.
SA515360229B1 (ar) مثبطات‎ ‎عامل التمايز والنمو 8‏
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
EA201200618A1 (ru) Производные хроменона с антиопухолевой активностью
WO2008054544A3 (en) Method for delivery across the blood brain barrier
BRPI0608152A2 (pt) formulações para tratamento ocular
MX338088B (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
SI1778680T1 (sl) Spirociklični cikloheksanski derivati
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
EA201270629A1 (ru) Новые полиморфные формы метил(4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил)карбамата
WO2011118954A3 (ko) 사람 하비갑개 유래 중간엽 기질세포로부터 연골, 골, 신경세포 또는 지방세포를 분화시키는 방법
JP2013515676A5 (OSRAM)
BR112014009761B8 (pt) Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
WO2008121422A3 (en) Implantable cell matrix composition for delivery of bioactive compounds
BR112013026644A2 (pt) método para a modulação da atividade de citocina
BRPI0716423A2 (pt) Terapêutica promotora de restauração de nervo espinhal contendo desacil grelina ou seus derivados como ingrediente ativo
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SENJU PHARMACEUTICAL CO., LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018.